Supported by an independent educational grant from Jazz Pharmaceuticals, Inc.

Homepage

Faculty

Craig Chepke, MD, DFAPA

Rakesh Jain, MD, MPH

Desiree Matthews, PMHNP-BC

Jonathan Meyer, MD

Some Title

Some place

Featured

Education

VMAT-2 Inhibitors – Mechanism and Evidence at a Glance

Videos

Anticholinergics and VMAT-2 Inhibitors: Different MOAs, Different Results

Education

Hypersomnolence Disorders and Comorbid Mental Illness

Recognizing and Evaluating Symptoms of Cataplexy and/or EDS in Psychiatric Patients

Program Modules

Education

VMAT-2 Inhibitors – Mechanism and Evidence at a Glance

Moving Mountains with Molecules in Tardive Dyskinesia Module 3

Education

Choosing Between VMAT-2 Inhibitors – A Pharmacologic Perspective

Moving Mountains with Molecules in Tardive Dyskinesia Module 4

Education

Tools & Techniques for TD Screening and Monitoring

Diagnosing TD – What It Is and What It Isn’t

TD Is More Than A Movement Disorder

Videos

Telehealth AIMS Demo

Anticholinergics and VMAT-2 Inhibitors: Different MOAs, Different Results

AIMS Severity Assessment Video Library

Podcasts

Beyond the Side Effect: Understanding and Addressing Tardive Dyskinesia

The Hidden Toll of Tardive Dyskinesia: Beyond Movement Symptoms

Mastering VMAT-2 Inhibitors: Optimizing Treatment Strategies for TD

News

Patient Survey Identifies Barriers to TD Treatment

FDA Approves First Schizophrenia Treatment in Over 3 Decades

Posters

Patient Perspective on Barriers to Diagnosis and Treatment of Tardive Dyskinesia: Results From a Cross-Sectional Survey

Impact of Tardive Dyskinesia on Clinical Aspects and Quality of Life Based on Individuals’ Underlying Psychiatric Conditions: Interim Analysis of Baseline Data From the IMPACT-TD Registry

Once-Daily Valbenazine for Tardive Dyskinesia or Huntington’s Disease Chorea in Patients with Dysphagia or Swallowing Difficulties